Doxepin (silenor) for insomnia

American Family Physician

Volumn 84, Issue 4, 2011, Pages 453-454

  Patel, Dhiren ^a   Goldman Levine, Jennifer D ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DOXEPIN; PLACEBO;

ANTICHOLINERGIC SYNDROME; ARTICLE; BEDTIME DOSAGE; DOSE RESPONSE; DRUG COMPETITION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; LOW DRUG DOSE; MEMORY DISORDER; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 80051754444     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Silenor (doxepin) [prescribing information]. San Diego, Calif.: Somaxon Pharmaceuticals, Inc.; 2010. http://www.silenor.com/pub/downloadashx?key=%2fwECFQ%3d%3d. Accessed November 1, 2010.
2. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555-1561.
3. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2008;69(10):1557-1564.
4. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33(11):1553-1561.